<DOC>
	<DOCNO>NCT01942603</DOCNO>
	<brief_summary>The purpose registry collect data order discover whether melanoma patient minimal SN tumor burden undergo complete lymph node dissection ( CLND ) . Currently , patient positive ( metastatic ) SN , patient offer CLND , surgical intervention aim remove lymph node nodal basin SN . However , positive ( metastatic ) SN minimally involve , center and/or country offer CLND routinely . As matter fact , CLND procedure increase survival patient minimal SN tumor burden , add prognostic information , potentially useful subsequent decision-making process . However , surgical operation patient , might accompany significant side effect . Moreover , approximately 20 % patient metastatic SN lymph node metastasis basin , mean 4 patient 5 benefit CLND . Thus , urgent need identify SN positive patient could safely spar CLND . It demonstrate breast cancer patient minimal SN tumor burden safely manage nodal observation , without perform CLND . There evidence situation exist melanoma well , need validate conduct registry . The result registry crucial establish accept standard care ( CLND nodal observation ) melanoma patient minimal SN tumor burden .</brief_summary>
	<brief_title>Minimal SN Tumor Burden</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>18 year age old Histological evidence primary cutaneous melanoma Metastases solely confine within SN : subcapsular space ( parenchymal infiltration ) maximum diameter large metastasis great 0.4 mm regardless site , submicrometastasis maximum diameter great 0.1 mm If 1 metastatic SN , patient still eligible provide involved SN minimal tumor burden , regardless amount positive SNs interested basin No history malignancy within past 5 year , except nonmelanoma skin cancer ( Basal Cell Carcinomas Squamous Cell Carcinomas ) situ cervical cancer Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Minimal ( SN ) tumor burden</keyword>
	<keyword>Stage III</keyword>
	<keyword>Patients</keyword>
	<keyword>Lymphnode Dissections</keyword>
</DOC>